Trial
NCT03437070
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Miami
Collaborators
Janssen Scientific Affairs, LLC
Condition
Leiomyosarcoma
Intervention
Trabectedin
Why stopped
Sponsor Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-18